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Since the seminal description of the “cycle of quality” by
Califf et al. (1) in 2002, in which the evidence established
from randomized clinical trials and codiﬁed in practice
guidelines was to be used to develop quality indicators and
performance measures and adherence to which could be
assessed in practice registries and fed back to providers
in a loop of performance improvement, the relationship
between performance and outcomes in acute cardiovascular
care has been ﬁrmly established. The CRUSADE (Can
Rapid Risk Stratiﬁcation of Unstable Angina Patients
Suppress Adverse Outcomes With Early Implementation of
the American College of Cardiology/American Heart
Association Guidelines) National Quality Improvement
Initiative demonstrated that every 10% improvement in
adherence to guidelines recommendations was associated
with a 10% reduction in in-hospital mortality (odds ratio,
0.90 [95% conﬁdence interval: 0.84 to 0.97]) (2). In addi-See page 539tion, the important role of performance improvement
programs and feedback to physicians and hospitals in
improving adherence to guidelines has become clear. Not
only have these programs improved adherence to guidelines
recommendations (3), but they have also led to reductions in
disparities in care (4). In fact, these programs have been so
successful that a recent report from the National Cardio-
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DSI-Lilly.based on key metrics of quality for acute and discharge
treatment of patients with acute myocardial infarction
(AMI) among hospitals participating in the NCDR
ACTION (Acute Coronary Treatment and Intervention
Outcomes Network)-GWTG (Get With The Guidelines)
registry was so high and that the gap between leading (90th
percentile) and lagging (10th percentile) centers had become
so narrow that only limited room for incremental improve-
ment remained in the arena of acute coronary care. For
example, in 2011, the overall AMI performance composite
scores at the 10th percentile of participating hospitals in the
ACTION-GWTG registry were 84.3%, 94.4% at the 50th
percentile, and 98.6% at the 90th percentile of hospitals (5).
In 2011, in the CathPCI (Catheterization PCI) registry,
discharge use of aspirin (97.9%), thienopyridines (97.3%),
beta-blockers (86.3%), and lipid-lowering agents (92.5%)
among eligible patients undergoing percutaneous coronary
intervention (PCI) was also similarly high (5).
While these successes in improving the rates and
consistency of in-hospital and discharge use of guideline-
based treatments among patients with acute coronary
disease and those treated with PCI should be celebrated,
achieving such high levels of performance in secondary
prevention have long been a challenge. In a single-center
study of long-term adherence to secondary prevention
treatment in 2002, the prevalence of aspirin use among
coronary artery disease (CAD) patients was 83%, 61% for
beta-blocker use, 63% for lipid-lowering therapy, and only
39% for use of all 3. Consistent use was below 50% for
all agents except aspirin (6). A 2003 broad survey of the
quality of health care for adults in the United States (7)
found that of 37 quality indicators in coronary artery
disease, the percentage of recommended care received was
only 68.0% (64.2% to 71.8%); and a 2004 publication from
the GRACE (Global Registry of Acute Coronary Events)
registry noted that even among patients discharged on
aspirin, beta-blocker, angiotensin-converting enzyme (ACE)
inhibitor, or statin therapy, discontinuation rates at 6 months
were 8% for aspirin, 12% for beta-blockers, 20% for ACE
inhibitors, and 13% for statins (8).
A decade after these initial observations, the work by
Maddox et al. (9) in this issue of the Journal highlights
a persistent and disturbing failure to sustain the high levels
of treatment observed in the acute and discharge settings in
the 2011 NCDR registries into chronic secondary preven-
tion for CAD in the outpatient setting. Using the NCDR
PINNACLE (Practice INNovation And CLinical Excel-
lence) registry created in 2008, which was designed specif-
ically to measure the quality of cardiovascular care in the
outpatient setting, Maddox et al. demonstrated that among
58 participating outpatient practices and a total of 156,145
CAD patients, the combination of beta-blockers, statins,
and ACE inhibitors/angiotensin receptor blockers (ARBs)
was prescribed as appropriate for eligible patients only
66.5% of the time at the ﬁrst documented visit, which
increased only slightly to 69.7% after accounting for all
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548visits within a year of the initial encounter. Just as shown
with acute and discharge care, which has been the focus of
quality improvement in cardiovascular care over that past
decade, there was wide variation in the rate of optimal
prescription (from 28% to 100%; median: 73.5%) across the
58 practices and a 25% chance that similar patients treated
at 2 different practices would receive different care. These
data suggest substantial opportunities to improve quality of
care through systematic application of provider feedback and
best practices in process improvement. Importantly,
preliminary data from 29 practices with pre- and post-
PINNACLE participation data showed that sites were
14% more likely to prescribe the optimal combination of
medications after initiating PINNACLE participation.
However, length of participation in the PINNACLE
registry was not associated with increased optimal prescrip-
tion, suggesting that participation in a quality improvement
registry is an important component for enhancing quality of
care but insufﬁcient to achieve a sustained trajectory of
improvement and high rates of evidence-based secondary
prevention medication use in the outpatient setting.
Unlike inpatient prescribing and discharge prescribing
after an acute coronary syndrome, achieving high rates of
outpatient secondary prevention treatment may be more
challenging as the diversity of inﬂuences (some measured in
the PINNACLE registry and others not) on measured
performance will likely be greater in the outpatient setting.
For example, to ensure optimal prescription of evidence-
based secondary prevention medications, systematic appro-
aches must include, and may be more dependent upon,
efforts aimed at engaging a wider spectrum of providers,
including not only cardiologists but also family practice
physicians, internists, gynecologists, and advanced practice
providers (nurse practitioners and physician assistants) who
together, compared with acute inpatient care, may provide
a larger portion of post-hospitalization care opportunities
than cardiologists for patients with CAD post-MI or PCI,
particularly as care becomes more temporally remote to the
initial event. In this regard, it is of concern that diabetes
was associated not only with lower prescription of optimal
combination care but also lower prescription of ACE
inhibitors or ARBs, for which clear renoprotective indica-
tions in diabetes also exist, suggesting that broader perfor-
mance improvement initiatives may be needed.
Furthermore, care in the outpatient setting may be more
geographically diffuse, with patients receiving PCI or treated
for AMI at a given hospital dispersed among many primary
providers and/or cardiology practices for follow-up care.
Translating from the successes of integrated systems-based
approaches to improving time to reperfusion in ST-segment
elevation MI care may offer particular insights in this
regard. Novel information technology solutions, including
harnessing electronic health records systems and enabling
integration of hospitals, outpatient practices, and pharmaciesto ensure systematic information-based approaches to care,
as well as integrating social media and other innovative
approaches to educate, engage, and empower patients to
participate in their own health care will almost certainly be
necessary. In addition, despite the promise of the Affordable
Care Act, consideration of costs of care at the point of care
to ensure that all patients can obtain their prescribed medi-
cations and efforts to ensure the development and avail-
ability of tools and strategies to enhance patient compliance
will remain factors in improving outcomes in secondary
prevention.
In summary, the work of Maddox et al. (9) has once again
called our attention to the substantial deﬁciencies in and
challenges of attaining consistent, high-quality, evidence-
based cardiovascular secondary prevention care in our
outpatient practices. We must ensure that unlike previous
reports, dating to more than a decade ago, this will be more
than a shot across the bow and that we will collectively take
action, embracing quality improvement initiatives like the
PINNACLE registry and others, building on the past
successes in acute cardiovascular care, and ensuring that the
cycle of quality continues to turn.
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